Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Covington
Citi
Boehringer Ingelheim
US Army
AstraZeneca
UBS
Queensland Health

Generated: June 25, 2018

DrugPatentWatch Database Preview

Schering Company Profile

« Back to Dashboard

Summary for Schering
International Patents:179
US Patents:6
Tradenames:64
Ingredients:56
NDAs:102
Patent Litigation for Schering: See patent lawsuits for Schering

Drugs and US Patents for Schering

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering ETRAFON 2-10 amitriptyline hydrochloride; perphenazine TABLET;ORAL 014713-007 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Schering NOXAFIL posaconazole SUSPENSION;ORAL 022003-001 Sep 15, 2006 RX Yes Yes 8,263,600 ➤ Sign Up Y ➤ Sign Up
Schering GARAMYCIN gentamicin sulfate SOLUTION/DROPS;OPHTHALMIC 050039-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Schering CELESTONE betamethasone CREAM;TOPICAL 014762-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Schering

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering DIPROLENE betamethasone dipropionate CREAM, AUGMENTED;TOPICAL 019408-001 Jan 31, 1986 4,489,070 ➤ Sign Up
Schering Plough LOTRIMIN clotrimazole CREAM;TOPICAL 017619-001 Approved Prior to Jan 1, 1982 3,705,172 ➤ Sign Up
Schering OPTIMINE azatadine maleate TABLET;ORAL 017601-001 Approved Prior to Jan 1, 1982 3,717,647 ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-004 Dec 29, 1994 4,470,972 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SCHERING drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 2008-09-30
➤ Subscribe Injection 0.75 mg/mL, 100 mL vial ➤ Subscribe 2009-06-05
➤ Subscribe Delayed-release Tablets 100 mg ➤ Subscribe 2014-06-16
➤ Subscribe Injection 2 mg/mL, 100 mL vial ➤ Subscribe 2008-12-18
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2011-02-28
➤ Subscribe Injection 18 mg/mL, 16.7 mL vials ➤ Subscribe 2015-11-24

Non-Orange Book US Patents for Schering

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,710,154 Tetrahydrofuran antifungals ➤ Sign Up
6,713,481 Crystalline antifungal polymorph ➤ Sign Up
5,693,626 Tetrahydrofuran antifungals ➤ Sign Up
5,703,236 Tetrahydrofuran antifungals ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Schering Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0038 France ➤ Sign Up PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
12/008 Ireland ➤ Sign Up PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
216 Luxembourg ➤ Sign Up 91216, EXPIRES: 20191220
C/GB06/007 United Kingdom ➤ Sign Up PRODUCT NAME: POSACONAZOLE, OPTIONALLY IN THE FORM OF AN ESTER OR PHARMACEUTICALLY ACCEPTABLE SALT.; REGISTERED: UK EU/1/05/320/001 20051025; UK EU/1/05/321/001 20051025
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
US Department of Justice
Johnson and Johnson
Moodys
UBS
Harvard Business School
Colorcon
Chubb
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.